997 resultados para 11-103
Resumo:
Référence bibliographique : Rol, 56809
Resumo:
Here, we present a review of the dataset resulting from the 11-years follow-up of Trypanosoma cruziinfection in free-ranging populations of Leontopithecus rosalia(golden lion tamarin) andLeontopithecus chrysomelas(golden-headed lion tamarin) from distinct forest fragments in Atlantic Coastal Rainforest. Additionally, we present new data regarding T. cruziinfection of small mammals (rodents and marsupials) that live in the same areas as golden lion tamarins and characterisation at discrete typing unit (DTU) level of 77 of these isolates. DTU TcII was found to exclusively infect primates, while TcI infectedDidelphis aurita and lion tamarins. The majority ofT. cruziisolates derived from L. rosaliawere shown to be TcII (33 out 42) Nine T. cruziisolates displayed a TcI profile. Golden-headed lion tamarins demonstrated to be excellent reservoirs of TcII, as 24 of 26 T. cruziisolates exhibited the TcII profile. We concluded the following: (i) the transmission cycle of T. cruziin a same host species and forest fragment is modified over time, (ii) the infectivity competence of the golden lion tamarin population fluctuates in waves that peak every other year and (iii) both golden and golden-headed lion tamarins are able to maintain long-lasting infections by TcII and TcI.
Resumo:
La persistència de la crisi econòmica suposa una amenaça constant al món de la comunicació, especialment per les dimensions dels pressupostos de publicitat, i ha fomentat que els directors de marketing exigeixin retorn, medició i la màxima eficiència en les seves inversions. El clipping de mitjans s’ha convertit en una eina imprescindible per valorar l’eficàcia, comprendre la repercusió, conèixer el retorn d’inversió aconseguit, en definitiva, analitzar si sh´an complert els objetius de la campaña de publicitat. No només es tracta d’una forma de conèixer les aparicions aconseguides en els mitjans, sinó també de reportar al client els assoliments obtinguts. Aquest estudi pretén demostrar la importància d’establir unes pautes i uns paràmetres universals en la valoració de la comunicació d’una marca, producte o servei en els mitjans de comunicació. L’anàlisi que s’ha dut a terme en aquest treball es compon d’opinions de diversos professionals del sector, bibliografia i comparacions amb altres estudis de la mateixa temàtica en altres països.
Resumo:
Donateur : Clermont, Raoul de (18..-19..?)
Resumo:
Référence bibliographique : Rol, 56903
Resumo:
Référence bibliographique : Rol, 56838
Resumo:
Référence bibliographique : Rol, 56820
Resumo:
INTRODUCTION Rilpivirine (RPV) has a better lipid profile than efavirenz (EFV) in naïve patients (1). Switching to RPV may be convenient for many patients, while maintaining a good immunovirological control (2). The aim of this study was to analyze lipid changes in HIV-patients at 24 weeks after switching to Eviplera® (emtricitabine/RPV/tenofovir disoproxil fumarate [FTC/RPV/TDF]). MATERIALS AND METHODS Retrospective, multicentre study of a cohort of asymptomatic HIV-patients who switched from a regimen based on 2 nucleoside reverse transcriptase inhibitors (NRTI)+protease inhibitor (PI)/non nucleoside reverse transcriptase inhibitor (NNRTI) or ritonavir boosted PI monotherapy to Eviplera® during February-December, 2013; all had undetectable HIV viral load for ≥3 months prior to switching. Patients with previous failures on antiretroviral therapy (ART) including TDF and/or FTC/3TC, with genotype tests showing resistance to components of Eviplera®, or who had changed the third drug of the ART during the study period were excluded. Changes in lipid profile and cardiovascular risk (CVR), and efficacy and safety at 24 weeks were analyzed. RESULTS Among 305 patients included in the study, 298 were analyzed (7 cases were excluded due to lack of data). Men 81.2%, mean age 44.5 years, 75.8% of HIV sexually transmitted. 233 (78.2%) patients switched from a regimen based on 2 NRTI+NNRTI (90.5% EFV/FTC/TDF). The most frequent reasons for switching were central nervous system (CNS) adverse events (31.0%), convenience (27.6%) and metabolic disorders (23.2%). At this time, 293 patients have reached 24 weeks: 281 (95.9%) have continued Eviplera®, 6 stopped it (3 adverse events, 2 virologic failures, 1 discontinuation) and 6 have been lost to follow up. Lipid profiles of 283 cases were available at 24 weeks and mean (mg/dL) baseline vs 24 weeks are: total cholesterol (193 vs 169; p=0.0001), HDL-c (49 vs 45; p=0.0001), LDL-c (114 vs 103; p=0.001), tryglycerides (158 vs 115; p=0.0001), total cholesterol to HDL-c ratio (4.2 vs 4.1; p=0.3). CVR decreased (8.7 vs 7.5%; p= 0.0001). CD4 counts were similar to baseline (653 vs 674 cells/µL; p=0.08), and 274 (96.8%) patients maintained viral suppression. CONCLUSIONS At 24 weeks after switching to Eviplera®, lipid profile and CVR improved while maintaining a good immunovirological control. Most subjects switched to Eviplera® from a regimen based on NNRTI, mainly EFV/FTC/TDF. CNS adverse events, convenience and metabolic disorders were the most frequent reasons for switching.
Resumo:
Référence bibliographique : Rol, 56890
Resumo:
Référence bibliographique : Rol, 56881
Resumo:
Référence bibliographique : Rol, 56816
Resumo:
Référence bibliographique : Rol, 56815
Resumo:
Référence bibliographique : Rol, 56811
Resumo:
Référence bibliographique : Rol, 56765
